ADMA Biologics, Inc.
ADMA Biologics, Inc. Fundamental Analysis
ADMA Biologics, Inc. (ADMA) shows strong financial fundamentals with a PE ratio of 18.36, profit margin of 42.87%, and ROE of 53.98%. The company generates $0.5B in annual revenue with strong year-over-year growth of 65.15%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 83.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze ADMA's fundamental strength across five key dimensions:
Efficiency Score
ExcellentADMA demonstrates superior asset utilization.
Valuation Score
ExcellentADMA trades at attractive valuation levels.
Growth Score
ModerateADMA shows steady but slowing expansion.
Financial Health Score
ExcellentADMA maintains a strong and stable balance sheet.
Profitability Score
ExcellentADMA achieves industry-leading margins.
Key Financial Metrics
Is ADMA Expensive or Cheap?
P/E Ratio
ADMA trades at 18.36 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ADMA's PEG of 0.18 indicates potential undervaluation.
Price to Book
The market values ADMA Biologics, Inc. at 8.92 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 22.16 times EBITDA. This signals the market has high growth expectations.
How Well Does ADMA Make Money?
Net Profit Margin
For every $100 in sales, ADMA Biologics, Inc. keeps $42.87 as profit after all expenses.
Operating Margin
Core operations generate 34.19 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $53.98 in profit for every $100 of shareholder equity.
ROA
ADMA Biologics, Inc. generates $36.83 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
ADMA Biologics, Inc. produces operating cash flow of $64.81M, showing steady but balanced cash generation.
Free Cash Flow
ADMA Biologics, Inc. produces free cash flow of $40.62M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.17 in free cash annually.
FCF Yield
ADMA converts 1.05% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.36
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.92
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.85
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.19
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.13
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.54
vs 25 benchmark
ROA
Return on assets percentage
0.37
vs 25 benchmark
ROCE
Return on capital employed
0.33
vs 25 benchmark
How ADMA Stacks Against Its Sector Peers
| Metric | ADMA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.36 | 29.43 | Better (Cheaper) |
| ROE | 53.98% | 800.00% | Weak |
| Net Margin | 42.87% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.19 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 7.13 | 4.64 | Strong Liquidity |
| ROA | 36.83% | -17936.00% (disorted) | Strong |
ADMA outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews ADMA Biologics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
238.81%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
180.80%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
136.32%
Industry Style: Defensive, Growth, Innovation
High Growth